

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Debra A. Wojcik
Type or print name

Debra A. Wojcik
Signature

June 4, 2004
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
CARBONI ET AL.

APPLICATION NO: 10/814,199

FILED: MARCH 31, 2004

FOR: SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING
CANCER

Mail Stop **Box Amendment**
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


Some of the listed references are of record in parent Application No. 10047 NP (Serial No. 10/677,067) filed October 1, 2003, and in parent Application No. LD0318 NP (Serial No. 10/676,214) filed October 1, 2003, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

Also, copies of the other cited references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3453




Maureen S. Gibbons
Attorney for Applicants
Reg. No. 44,121

Date: *June 3, 2004*

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.
10106A CIP
APPLICATION NO.
10/814,199
APPLICANT
CARBONI ET AL.
FILING DATE
MARCH 31, 2004

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	6,337,338	1/8/02	Kozlowski et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AH	WO 03/048133	6/12/03	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AI	WO 01/25220	4/12/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AJ	WO 00/35455	6/22/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AK	WO 02/102804	12/27/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AL	WO 02/092599	11/21/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AM	Lu, Y., et al., "Insulin-like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)", Journal of the National Cancer Institute, Vol. 93, No. 24, pp. 1852-1857 (2001)
	AN	Normanno, N., et al., "Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth", Annals of Oncology 13, pp. 65-72 (2002)
	AO	Werner, H., et al., "The IGF I Receptor Gene: A Molecular Target for Disrupted Transcription Factors", Genes, Chromosomes & Cancer, Vol. 36, pp. 113-120 (2003)
	AP	Lu, D., et al., "Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody", The Journal of Biological Chemistry, Vol. 279, No. 4, pp. 2856-2865 (2004)
	AQ	Grothey, A., et al., "The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors", J. Cancer Res. Clin. Oncol., Vol. 125, pp. 166-173 (1999)
	AR	Camirand, A., et al., "Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells", Med. Sci. Monit., Vol. 8, No. 12, pp. BR521-BR526 (2002)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

10106A CIP

APPLICATION NO.

10/814,199

APPLICANT

CARBONI ET AL.

FILING DATE

MARCH 31, 2004

U.S. PATENT APPLICATION DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AS	U.S. Patent Appln. No. 10/676,214 (BMS Docket No. LD0318NP)	Filed 10/1/03	Carboni, et al.			
	AT	U.S. Patent Appln. No. 10/674,098 (BMS Docket No. LD0314NP)	Filed 9/29/03	Velaparthi, et al.			
	AU	U.S. Patent Appln. No. 10/263,448 (BMS Docket No. LD0227A CIP)	Filed 10/2/02	Wittman, et al.			
	AV	U.S. Patent Appln. No. 10/751,798 (BMS Docket No. LD0313 NP)	Filed 1/5/04	Beaulieu, et al.			
	AW	U.S. Patent Application No. 10/677,067 (BMS Docket No. 10047NP)	Filed 10/1/03	Carboni et al.			
	AX						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AY	WO 03/024967	3/27/03	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AZ	WO 03/035619	5/1/03	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BA	WO 03/035616	5/1/03	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BB	WO 03/018022	3/6/03	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BC	WO 02/053596	7/11/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BD	Traxler, P., "Protein tyrosine kinase inhibitors in cancer treatment", Exp. Opin. Ther. Patents, Vol. 7, pp. 571-588 (1997)
	BE	Ellis, M., et al., "Insulin-like growth factors in human breast cancer", Breast Cancer Research and Treatment, Vol. 52, pp. 175-184 (1998)
	BF	Werner, H., et al., "The IGF I Receptor Gene: A Molecular Target for Disrupted Transcription Factors", Genes, Chromosomes & Cancer, Vol. 36, pp. 113-120 (2003)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
10106A CIP
APPLICATION NO.
10/814,199
APPLICANT
CARBONI ET AL.
FILING DATE
MARCH 31, 2004

U.S. PATENT APPLICATION DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						
	BM						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	BN	WO 02/053596	7/11/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BO	WO 99/60023	11/25/99	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	Camirand, A., et al., "Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells", Med. Sci. Monit., Vol. 8, No. 12, pp. BR521-526 (2002)
	BS	Lu, D., et al., "Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Recombinant Bispecific Antibody", The Journal of Biological Chemistry, Vol. 279, No. 4, pp. 2856-2865 (2004)
	BT	Lu, Y., et al., "Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)", Journal of the National Cancer Institute, Vol. 92, No. 24, pp. 1852-1857 (2001)
	BU	Normanno, N., et al., "Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth", Annals of Oncology, Vol. 13, pp. 65-72 (2002)
	BV	Garcia-Echeverria, C., et al., "In vivo antitumor activity of NVP-AEW541 - A novel, potent, and selective inhibitor of the IGF-IR kinase", Cancer Cell, Vol. 5, pp. 231-239, March 2004
	BW	Mitsiades, C., et al., "Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors", Cancer Cell, Vol. 5, pp. 221-230, March 2004
	BX	Long, L., et al., "Loss of the Metastatic Phenotype in Murine Carcinoma Cells Expressing an Antisense RNA to the Insulin-like Growth Factor Receptor", Cancer Research, Vol. 55, pp. 1006-1009, March 1, 1995

EXAMINER	DATE CONSIDERED
----------	-----------------

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
10106A CIP
APPLICATION NO.
10/814,199
APPLICANT
CARBONI ET AL.
FILING DATE
MARCH 31, 2004

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		U.S. APPLICATION DOCUMENT	DATE OF PUBLICATION	NAME	CLASS	SUBCLASS	FILING DATE
	BY	2004/0001833 A1	1/1/04	Agus			
	BZ	2004/0057950 A1	3/25/04	Waksal et al.			

U.S. PATENT DOCUMENTS

	CA						
	CB						
	CC						
	CD						
	CE						
	CF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	CG	EP 0 385 850 A2	2/27/90	EP			<input type="checkbox"/>	<input type="checkbox"/>
	CH						<input type="checkbox"/>	<input type="checkbox"/>
	CI						<input type="checkbox"/>	<input type="checkbox"/>
	CJ						<input type="checkbox"/>	<input type="checkbox"/>
	CK						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	CL	Maloney, E., et al., "An Anti-Insulin-like Growth Factor I Receptor Antibody That Is a Potent Inhibitor of Cancer Cell Proliferation", Cancer Research, Vol. 63, pp. 5073-5083, August 15, 2003
	CM	Burtrum, D., et al., "A Fully Human Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor Blocks Ligand-Dependent Signaling and Inhibits Human Tumor Growth <i>in Vivo</i> ", Cancer Research, Vol. 63, pp. 8912-8921, December 15, 2003
	CN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.